Hamid Akbari Javar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hamid Akbari Javar has a total of 185 co-authors. Here are the top co-authors by number of shared publications:
- Ehsan Seyedjafari
School of Biotechnology, College of Science University of Tehran Tehran Iran
5 shared publications - Farid Abedin Dorkoosh
Department of Pharmaceutics, Faculty of Pharmacy Tehran University of Medical Sciences Tehran Iran
4 shared publications Zahra Esmaili
Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
4 shared publications- Amir Azadi
Shiraz University of Medical Sciences
3 shared publications Mohammad Raoufi
Nanotechnology Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
3 shared publications- Molood Alsadat Vakilinezhad
Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
3 shared publications
Latest Publications
- Open Access
- 21 September 2026
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 25 (10) , e71202
Preparation and Characterization of Azelaic Acid‐Loaded Nanofiber Scaffold as Anti‐Acne and Depigmenting Care, Fabricated by Electrospinning Method
Objective: Acne vulgaris is a common dermatological concern, and conventional topical azelaic acid formulations may have limitations in skin residence time and tolerability. Polymeric nanofiber scaffolds offer a promising platform for topical drug delivery. This study aimed to develop and characterize chitosan/polyvinyl alcohol (CS/PVA) electrospun nanofibers loaded with azelaic acid for potential use in acne management. Method: Azelaic acid‐loaded CS/PVA nanofibers were prepared by electrospinning. Morphology was evaluated by scanning electron microscopy, in vitro drug release was assessed by an immersion method, antibacterial activity against Cutibacterium acnes was determined by disk diffusion, and physicochemical stability was examined under accelerated conditions. Results: Nanofibers containing 9% PVA, 2% chitosan, and 50 or 70% azelaic acid showed uniform, bead‐free morphology and suitable physical and mechanical properties under optimized electrospinning conditions. The azelaic acid‐loaded scaffolds exhibited antimicrobial activity against C. acnes , acceptable stability, and a sustained release profile, with the 70% formulation releasing over approximately 89% of the drug within 24 h. Conclusion: Azelaic acid‐loaded CS/PVA nanofiber scaffolds demonstrated favorable in vitro physicochemical and antibacterial properties as topical delivery systems. The 70% azelaic acid formulation was selected as the optimized scaffold for further preclinical investigation, while in vivo and clinical studies are needed to evaluate its therapeutic efficacy and safety.
- 21 September 2026
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 25 (10) , e71202
Open AccessPreparation and Characterization of Azelaic Acid‐Loaded Nanofiber Scaffold as Anti‐Acne and Depigmenting Care, Fabricated by Electrospinning Method
Objective: Acne vulgaris is a common dermatological concern, and conventional topical azelaic acid formulations may have limitations in skin residence time and tolerability. Polymeric nanofiber scaffolds offer a promising platform for topical drug delivery. This study aimed to develop and characterize chitosan/polyvinyl alcohol (CS/PVA) electrospun nanofibers loaded with azelaic acid for potential use in acne management. Method: Azelaic acid‐loaded CS/PVA nanofibers were prepared by electrospinning. Morphology was evaluated by scanning electron microscopy, in vitro drug release was assessed by an immersion method, antibacterial activity against Cutibacterium acnes was determined by disk diffusion, and physicochemical stability was examined under accelerated conditions. Results: Nanofibers containing 9% PVA, 2% chitosan, and 50 or 70% azelaic acid showed uniform, bead‐free morphology and suitable physical and mechanical properties under optimized electrospinning conditions. The azelaic acid‐loaded scaffolds exhibited antimicrobial activity against C. acnes , acceptable stability, and a sustained release profile, with the 70% formulation releasing over approximately 89% of the drug within 24 h. Conclusion: Azelaic acid‐loaded CS/PVA nanofiber scaffolds demonstrated favorable in vitro physicochemical and antibacterial properties as topical delivery systems. The 70% azelaic acid formulation was selected as the optimized scaffold for further preclinical investigation, while in vivo and clinical studies are needed to evaluate its therapeutic efficacy and safety.
- Open Access
- 26 August 2026
- Published by Elsevier in SSRN Electronic Journal
Colchicine-Loaded Niosome-in-Film Nanoplatform: Physicochemical Characterization, Film Performance, and Comparative In Vitro Release
This study aimed to develop and physiochemically characterize a colchicine-loaded niosome-in-film system and to determine whether incorporation of colchicine-loaded nanovesicles into a film-forming polymeric matrix modifies in vitro drug release compared with free niosomal dispersion and a non-niosomal colchicine-containing film. Colchicine-loaded niosomes were prepared, characterized, and incorporated into a polymeric film-forming gel. The resulting system was evaluated for vesicle characteristics, entrapment efficiency, rheological behavior, film-forming properties, mechanical performance, and in vitro drug release through a synthetic polyvinylidene fluoride (PVDF) membrane. Preliminary local tolerability was also assessed under the tested animal conditions. The selected niosomal formulation showed a mean hydrodynamic diameter of 155.1 nm, a polydispersity index (PDI) of 0.333, a zeta potential of -35.60 mV, and an entrapment efficiency of 68.24%. Incorporation into the film-forming matrix produced a flexible, non-sticky film with shear-thinning behavior. At 24 h, cumulative colchicine release from the niosome-in-film system reached 80.67%, with significantly lower overall in vitro release exposure than both comparator formulations. Preliminary irritation and sensitization assessments showed minimal irritation and no observed sensitization under the tested conditions. Overall, the niosome-in-film system provided a slower formulation-dependent in vitro release profile while retaining suitable physicochemical and film-forming characteristics. However, biological skin permeation, dermal deposition, pharmacokinetics, systemic exposure, and therapeutic efficacy were not investigated.
- 26 August 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessColchicine-Loaded Niosome-in-Film Nanoplatform: Physicochemical Characterization, Film Performance, and Comparative In Vitro Release
This study aimed to develop and physiochemically characterize a colchicine-loaded niosome-in-film system and to determine whether incorporation of colchicine-loaded nanovesicles into a film-forming polymeric matrix modifies in vitro drug release compared with free niosomal dispersion and a non-niosomal colchicine-containing film. Colchicine-loaded niosomes were prepared, characterized, and incorporated into a polymeric film-forming gel. The resulting system was evaluated for vesicle characteristics, entrapment efficiency, rheological behavior, film-forming properties, mechanical performance, and in vitro drug release through a synthetic polyvinylidene fluoride (PVDF) membrane. Preliminary local tolerability was also assessed under the tested animal conditions. The selected niosomal formulation showed a mean hydrodynamic diameter of 155.1 nm, a polydispersity index (PDI) of 0.333, a zeta potential of -35.60 mV, and an entrapment efficiency of 68.24%. Incorporation into the film-forming matrix produced a flexible, non-sticky film with shear-thinning behavior. At 24 h, cumulative colchicine release from the niosome-in-film system reached 80.67%, with significantly lower overall in vitro release exposure than both comparator formulations. Preliminary irritation and sensitization assessments showed minimal irritation and no observed sensitization under the tested conditions. Overall, the niosome-in-film system provided a slower formulation-dependent in vitro release profile while retaining suitable physicochemical and film-forming characteristics. However, biological skin permeation, dermal deposition, pharmacokinetics, systemic exposure, and therapeutic efficacy were not investigated.
- Open Access
- 9 August 2026
- Published by Brieflands in Jundishapur Journal of Natural Pharmaceutical Products
- Vol. 21 (3) , e171846
Boswellia sacra Flueck. Oleo-gum-resin Nanophytosome: Development, Standardization, and Cholinesterase Inhibitory Potential
Background: Alzheimer’s disease (AD) is a progressive neurodegenerative disorder associated with cholinergic dysfunction. The limited efficacy of current acetylcholinesterase inhibitors underscores the need for novel therapeutic approaches. Objectives: This study evaluated the acetylcholinesterase inhibitory activity of Boswellia sacra extracts and their phytosomal formulations. Methods: The methanolic extract of B. sacra was fractionated using potassium hydroxide (KOH) and ethyl acetate to obtain a boswellic acid-enriched fraction, which was further purified by silica gel chromatography to yield two derivatives identified by 1H and 13C nuclear magnetic resonance (NMR) spectroscopy. A phytosomal formulation was prepared using soy lecithin and cholesterol via high-shear homogenization followed by ultrasonication. The optimized nanophytosome was characterized by dynamic light scattering (DLS), Fourier transform infrared (FTIR) spectroscopy, differential scanning calorimetry (DSC), transmission electron microscopy (TEM), and scanning electron microscopy (SEM). Entrapment efficiency, stability, the in vivo release profile, cholinesterase inhibitory activity was assessed using Ellman’s method. Results: Phytochemical analysis yielded 3-acetyl-11-keto-boswellic acid (1) and 11-keto-boswellic acid (2), and compound 1 was used for standardization. The optimized phytosome exhibited a mean particle size of 112 ± 12.28 nm, a polydispersity index (PDI) of 0.23 ± 0.1, a zeta potential of -53 ± 5.87 mV, and an entrapment efficiency of 75.3 ± 1.47%. FTIR and DSC confirmed molecular interactions between lecithin and the extract, whereas TEM and SEM revealed spherical morphology. The optimized phytosomal formulation demonstrated a gradual release profile, reaching 92% after 12 hours, and increased acetylcholinesterase inhibition to 61.0 ± 10.7% (half-maximal inhibitory concentration [IC50], 177.9 ± 26.8 µg/mL) compared with the non-formulated extract. It also showed moderate butyrylcholinesterase inhibition (42 - 48%) and selectivity for acetylcholinesterase inhibition. Conclusions: The optimized phytosomal formulation enhanced in vitro acetylcholinesterase inhibitory activity compared with the non-formulated extract, indicating the potential of this delivery system to improve the biological activity of Boswellia constituents in cell-free enzyme assays. However, these findings are preliminary and limited to in vitro experiments. Further studies are required to assess blood–brain barrier permeability, neuronal uptake, pharmacokinetics, and in vivo therapeutic efficacy.
- 9 August 2026
- Published by Brieflands in Jundishapur Journal of Natural Pharmaceutical Products
- Vol. 21 (3) , e171846
Open AccessBoswellia sacra Flueck. Oleo-gum-resin Nanophytosome: Development, Standardization, and Cholinesterase Inhibitory Potential
Background: Alzheimer’s disease (AD) is a progressive neurodegenerative disorder associated with cholinergic dysfunction. The limited efficacy of current acetylcholinesterase inhibitors underscores the need for novel therapeutic approaches. Objectives: This study evaluated the acetylcholinesterase inhibitory activity of Boswellia sacra extracts and their phytosomal formulations. Methods: The methanolic extract of B. sacra was fractionated using potassium hydroxide (KOH) and ethyl acetate to obtain a boswellic acid-enriched fraction, which was further purified by silica gel chromatography to yield two derivatives identified by 1H and 13C nuclear magnetic resonance (NMR) spectroscopy. A phytosomal formulation was prepared using soy lecithin and cholesterol via high-shear homogenization followed by ultrasonication. The optimized nanophytosome was characterized by dynamic light scattering (DLS), Fourier transform infrared (FTIR) spectroscopy, differential scanning calorimetry (DSC), transmission electron microscopy (TEM), and scanning electron microscopy (SEM). Entrapment efficiency, stability, the in vivo release profile, cholinesterase inhibitory activity was assessed using Ellman’s method. Results: Phytochemical analysis yielded 3-acetyl-11-keto-boswellic acid (1) and 11-keto-boswellic acid (2), and compound 1 was used for standardization. The optimized phytosome exhibited a mean particle size of 112 ± 12.28 nm, a polydispersity index (PDI) of 0.23 ± 0.1, a zeta potential of -53 ± 5.87 mV, and an entrapment efficiency of 75.3 ± 1.47%. FTIR and DSC confirmed molecular interactions between lecithin and the extract, whereas TEM and SEM revealed spherical morphology. The optimized phytosomal formulation demonstrated a gradual release profile, reaching 92% after 12 hours, and increased acetylcholinesterase inhibition to 61.0 ± 10.7% (half-maximal inhibitory concentration [IC50], 177.9 ± 26.8 µg/mL) compared with the non-formulated extract. It also showed moderate butyrylcholinesterase inhibition (42 - 48%) and selectivity for acetylcholinesterase inhibition. Conclusions: The optimized phytosomal formulation enhanced in vitro acetylcholinesterase inhibitory activity compared with the non-formulated extract, indicating the potential of this delivery system to improve the biological activity of Boswellia constituents in cell-free enzyme assays. However, these findings are preliminary and limited to in vitro experiments. Further studies are required to assess blood–brain barrier permeability, neuronal uptake, pharmacokinetics, and in vivo therapeutic efficacy.
- 3 July 2026
- Published by Taylor & Francis in Pharmaceutical Development and Technology
- Vol. 31 (6) , 1090-1107
A process-free setup for the preparation of probiotic-loaded electrospun mat as a tailored dressing
- 3 July 2026
- Published by Taylor & Francis in Pharmaceutical Development and Technology
- Vol. 31 (6) , 1090-1107
A process-free setup for the preparation of probiotic-loaded electrospun mat as a tailored dressing
- Open Access
- 6 March 2026
- Published by Elsevier in SSRN Electronic Journal
Hyaluronic Acid-Cyclosporine A Nanomicelles for Enhanced Ocular Delivery and Therapeutic Efficacy in Dry Eye Disease
Dry eye disease (DED) is a prevalent and multifactorial condition affecting a significant proportion of the global population (~30%), characterized by ocular discomfort, visual disturbances, and chronic inflammation. Cyclosporine A (CyA), a potent immunomodulatory agent, is widely used for DED treatment, but its clinical application is limited by poor water solubility, low ocular bioavailability, rapid clearance, and irritation associated with conventional oil-based formulations. To address these challenges, we developed hyaluronic acid-conjugated CyA (HA-CyA) nanomicelles to enhance ocular retention, targeted cellular uptake, and therapeutic efficacy. HA-CyA was synthesized via a click reaction between propargylated hyaluronic acid and azidated CyA, forming self-assembled nanomicelles in an aqueous solution. The nanomicelles were characterized for particle size, zeta potential, morphology, critical micelle concentration, drug loading, and enzymatic-triggered release. In vitro studies demonstrated high biocompatibility, minimal irritancy, and efficient uptake in human corneal epithelial cells, mediated in part by HA-CD44 interactions. In vivo safety evaluation in rabbits confirmed the absence of ocular toxicity, epithelial defects, or apoptosis. Therapeutic efficacy in atropine-induced DED rabbit models showed that HA-CyA nanomicelles significantly improved tear production, tear film stability, and corneal epithelial integrity, while reducing inflammatory cytokines (TNF-α, IL-1β) compared with commercially available 0.05% CyA eye drops (Restasis®) and 0.15% HA artificial tears (Artipic Advanced®). These findings highlight HA-CyA nanomicelles as a novel, targeted ocular drug delivery platform with prolonged retention, reduced irritation, and effective anti-inflammatory activity for DED management.
- 6 March 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessHyaluronic Acid-Cyclosporine A Nanomicelles for Enhanced Ocular Delivery and Therapeutic Efficacy in Dry Eye Disease
Dry eye disease (DED) is a prevalent and multifactorial condition affecting a significant proportion of the global population (~30%), characterized by ocular discomfort, visual disturbances, and chronic inflammation. Cyclosporine A (CyA), a potent immunomodulatory agent, is widely used for DED treatment, but its clinical application is limited by poor water solubility, low ocular bioavailability, rapid clearance, and irritation associated with conventional oil-based formulations. To address these challenges, we developed hyaluronic acid-conjugated CyA (HA-CyA) nanomicelles to enhance ocular retention, targeted cellular uptake, and therapeutic efficacy. HA-CyA was synthesized via a click reaction between propargylated hyaluronic acid and azidated CyA, forming self-assembled nanomicelles in an aqueous solution. The nanomicelles were characterized for particle size, zeta potential, morphology, critical micelle concentration, drug loading, and enzymatic-triggered release. In vitro studies demonstrated high biocompatibility, minimal irritancy, and efficient uptake in human corneal epithelial cells, mediated in part by HA-CD44 interactions. In vivo safety evaluation in rabbits confirmed the absence of ocular toxicity, epithelial defects, or apoptosis. Therapeutic efficacy in atropine-induced DED rabbit models showed that HA-CyA nanomicelles significantly improved tear production, tear film stability, and corneal epithelial integrity, while reducing inflammatory cytokines (TNF-α, IL-1β) compared with commercially available 0.05% CyA eye drops (Restasis®) and 0.15% HA artificial tears (Artipic Advanced®). These findings highlight HA-CyA nanomicelles as a novel, targeted ocular drug delivery platform with prolonged retention, reduced irritation, and effective anti-inflammatory activity for DED management.
- Open Access
- 30 September 2025
- Published by Springer Nature in Journal of Biological Engineering
- Vol. 19 (1)
Cinnamaldehyde/cinnamon essential oil loaded poly-L-lactic acid/ hydroxyapatite fibrous scaffolds as osteogenic differentiation enhancing system for bone tissue engineering applications
In this study, we developed electrospun poly-L-lactic acid (PLLA)/ hydroxyapatite (HA) fibers loaded with Cinnamaldehyde (Cin) or Cinnamon essential oil (E.O) as a dual-function system to modulate bone remodeling. Cin or E.O as a natural component inhibited the bone resorption same as the bone formation process. The electrospun fibers were characterized by SEM, FTIR, contact angle, and tensile test. The biocompatibility of scaffolds was evaluated by an MTT assessment. Additionally, the osteogenic potency of fibers was investigated by alkaline phosphatase (ALP) activity assay, Alizarin Red staining, calcium content assay, and the RT-PCR analysis. The cinnamon compounds release profile was studied over 12 days. The results demonstrated that PLLA/HA/Cin and PLLA/HA/E.O. fibers had bead-free, randomly oriented morphologies and suitable physicochemical properties for cell seeding and survival. The calcium level deposition and ALP activity of PLLA/HA/Cin and PLLA/HA/E.O significantly increased compared to the control group. Osteogenic-related gene expression including ALP, Runx2, osteocalcin, and osteonectin significantly upregulated in PLLA/HA/Cin fiber group. The results revealed that the PLLA/HA/Cin fiber with desirable osteogenic differentiation potency can be an appropriate candidate for bone tissue engineering applications.
- 30 September 2025
- Published by Springer Nature in Journal of Biological Engineering
- Vol. 19 (1)
Open AccessCinnamaldehyde/cinnamon essential oil loaded poly-L-lactic acid/ hydroxyapatite fibrous scaffolds as osteogenic differentiation enhancing system for bone tissue engineering applications
In this study, we developed electrospun poly-L-lactic acid (PLLA)/ hydroxyapatite (HA) fibers loaded with Cinnamaldehyde (Cin) or Cinnamon essential oil (E.O) as a dual-function system to modulate bone remodeling. Cin or E.O as a natural component inhibited the bone resorption same as the bone formation process. The electrospun fibers were characterized by SEM, FTIR, contact angle, and tensile test. The biocompatibility of scaffolds was evaluated by an MTT assessment. Additionally, the osteogenic potency of fibers was investigated by alkaline phosphatase (ALP) activity assay, Alizarin Red staining, calcium content assay, and the RT-PCR analysis. The cinnamon compounds release profile was studied over 12 days. The results demonstrated that PLLA/HA/Cin and PLLA/HA/E.O. fibers had bead-free, randomly oriented morphologies and suitable physicochemical properties for cell seeding and survival. The calcium level deposition and ALP activity of PLLA/HA/Cin and PLLA/HA/E.O significantly increased compared to the control group. Osteogenic-related gene expression including ALP, Runx2, osteocalcin, and osteonectin significantly upregulated in PLLA/HA/Cin fiber group. The results revealed that the PLLA/HA/Cin fiber with desirable osteogenic differentiation potency can be an appropriate candidate for bone tissue engineering applications.
- 9 August 2025
- Published by Elsevier in International Journal of Biological Macromolecules
- p. 146646
Corrigendum to “Smart multilayer chitosan-based nanofibers for burn wounds: pH-responsive dual release of diclofenac sodium & Hamamelis virginiana extract: From design to in vitro & in vivo evaluation” [Int. J. Biol. Macromol. volume 320 (2025) article no. 145826]
- 9 August 2025
- Published by Elsevier in International Journal of Biological Macromolecules
- p. 146646
Corrigendum to “Smart multilayer chitosan-based nanofibers for burn wounds: pH-responsive dual release of diclofenac sodium & Hamamelis virginiana extract: From design to in vitro & in vivo evaluation” [Int. J. Biol. Macromol. volume 320 (2025) article no. 145826]
- Open Access
- 21 February 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-11
Plasma treatment can efficiently increase the attachment of pancreatic circulatory tumor cells to the surface
Pancreatic cancer ranks as the fourth most common cause of cancer-related fatalities globally, with a notably low 5-year relative survival rate. We need to immediately develop fast, dependable, and noninvasive diagnostic techniques that can accurately identify pancreatic cancer at an early stage. The research project created a straightforward but effective method for detecting and increasing the amount of tumor cells that could bind to polystyrene (PS) well plates. To significantly improve the adhesion of the pancreatic cancer cell line PANC-1 on PS well plates, a 5-min exposure to high-power oxygen plasma was implemented. This treatment caused a significant increase in surface energy and roughness. Surface characterization was assessed by utilizing an atomic force microscope and X-ray photoelectron spectroscopy. Water contact angle measurement is used to assess the level of wettability present on the treated surface. To determine how well the circulatory tumor cells (CTCs) model adheres to a plasma-treated surface (PTS), appropriate amounts of mCherry-labeled PANC-1 cells are mixed into a sample of blood cells to mimic clinical conditions. After applying plasma treatment, the experiment achieved a 96% success rate in binding at 2 h, specifically for the PANC-1 cell type. Moreover, the platform demonstrated a considerable ability to attach to cancerous cells compared to non-cancerous cells found in blood. To summarize, this study has shown that non-thermal plasma treatment could be a novel and efficient method for the better adhesion of pancreatic cancer cells, with the benefits of being cost-effective and quick. It is necessary for additional research to be conducted to confirm the clinical efficacy of the method.
- 21 February 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-11
Open AccessPlasma treatment can efficiently increase the attachment of pancreatic circulatory tumor cells to the surface
Pancreatic cancer ranks as the fourth most common cause of cancer-related fatalities globally, with a notably low 5-year relative survival rate. We need to immediately develop fast, dependable, and noninvasive diagnostic techniques that can accurately identify pancreatic cancer at an early stage. The research project created a straightforward but effective method for detecting and increasing the amount of tumor cells that could bind to polystyrene (PS) well plates. To significantly improve the adhesion of the pancreatic cancer cell line PANC-1 on PS well plates, a 5-min exposure to high-power oxygen plasma was implemented. This treatment caused a significant increase in surface energy and roughness. Surface characterization was assessed by utilizing an atomic force microscope and X-ray photoelectron spectroscopy. Water contact angle measurement is used to assess the level of wettability present on the treated surface. To determine how well the circulatory tumor cells (CTCs) model adheres to a plasma-treated surface (PTS), appropriate amounts of mCherry-labeled PANC-1 cells are mixed into a sample of blood cells to mimic clinical conditions. After applying plasma treatment, the experiment achieved a 96% success rate in binding at 2 h, specifically for the PANC-1 cell type. Moreover, the platform demonstrated a considerable ability to attach to cancerous cells compared to non-cancerous cells found in blood. To summarize, this study has shown that non-thermal plasma treatment could be a novel and efficient method for the better adhesion of pancreatic cancer cells, with the benefits of being cost-effective and quick. It is necessary for additional research to be conducted to confirm the clinical efficacy of the method.
- 1 November 2024
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 183, 109261
Transformative artificial intelligence in gastric cancer: Advancements in diagnostic techniques
- 1 November 2024
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 183, 109261
Transformative artificial intelligence in gastric cancer: Advancements in diagnostic techniques